AMGN ▼ -0.2% - Amgen Inc.
$AMGN REDUCES RISK OF DEATH IN PATIENTS AT HIGH RISK FOR A FIRST HEART ATTACK OR STROKE.
Amgen shares declined 0.2% despite the company announcing positive clinical trial results showing its treatment reduces the risk of death in high-risk cardiovascular patients. The modest downward move suggests the market may have already priced in expectations for this outcome, or investors are weighing other factors such as manufacturing costs, market competition, or the regulatory pathway ahead for the therapy.
31-AUG-2026 05:16 AM ET
Share this post
More filings for $AMGN
AMGN ▲ +0.1% - Amgen Inc.Sep 14, 2026AMGN ▼ -0.4% - Amgen Inc.Sep 9, 2026AMGN ▼ -5.8% - Amgen Inc.Sep 8, 2026AMGN ▼ -7.1% - Amgen Inc.Sep 4, 2026AMGN ▲ +1.5% - Amgen Inc.Sep 2, 2026
View full $AMGN filing history →💬 Comments
Loading comments…
Leave a comment
